Cardiovascular disease remains the world's top killer, but early detection through better blood testing could dramatically ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can increase the risk of heart attacks and strokes.

For almost 60 years, measuring cholesterol levels in the blood has been the best way to identify individuals at high risk of ...

Researchers in Sweden and the US suggest measuring levels of lipoproteins may be a more accurate risk predictor.

BACKGROUND: Elevated plasma levels of Lp(a) [lipoprotein(a)] are a causal risk factor for coronary heart disease and stroke ...

In particular, the study suggests that hormone therapy may lower levels of lipoprotein(a), a genetic risk factor associated ...

The core of the lipoprotein, containing cholesterol ester and TG, is nonpolar and hydrophobic, and the outer layer of the lipoprotein particle (containing free cholesterol, phospholipid ...

Background: Differences exist between European and American guideline recommendations regarding targets for low-density lipoprotein cholesterol (LDL-C) levels after percutaneous coronary intervention ...

Those results have boosted the momentum of a decade-long surge of medical interest in lipoprotein (a), which remains a poorly understood variant of the well-known "bad" cholesterol low-density ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.

A recent study published in Obstetrics and Gynecology assesses hormone therapy (HT)-induced changes in cardiovascular ...

For almost 60 years, measuring cholesterol levels in the blood has been the best way to identify individuals at high risk of cardiovascular disease.